Universe Pharmaceuticals Inc Quick Ratio (UPC) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Universe Pharmaceuticals Inc  (NASDAQ: UPC)

Universe Pharmaceuticals Inc's Quick Ratio

UPC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 2.55 above Universe Pharmaceuticals Inc average.

Within Major Pharmaceutical Preparations industry 247 other companies have achieved higher Quick Ratio than Universe Pharmaceuticals Inc in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from to 899.

Explain Quick Ratio?
How much Cash & cash equivalents UPC´s has?
What are UPC´s Current Liabilities?




API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/UPC/financial-strength
https://api.csimarket.com/api/v1/companies/UPC/fundamentals
https://api.csimarket.com/api/v1/companies/UPC/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
UPC Quick Ratio (Sep 30 2025)
Q4
0
Q3
0
Q2
0
Q1
(Sep 30 2024)
Q4
Y / Y Current Liabilities Change 11.71 %
Y / Y Cash & cash equivalent Change 8.8 %
Quick Ratio MRQ 2.55
UPC's Total Ranking # 899
Seq. Current Liabilities Change 95.93 %
Seq. Cash & cash equivalent Change 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 248
Healthcare Sector # 415
Overall Market # 899


Quick Ratio Statistics
High Average Low
2.55 1.82 1.35
(Sep 30 2025)   (Sep 30 2023)




Financial Statements
Universe Pharmaceuticals Inc's Current Liabilities $ 13,174 Millions Visit UPC's Balance sheet
Universe Pharmaceuticals Inc's Cash & cash equivalent $ 33,592 Millions Visit UPC's Balance sheet
Source of UPC's Sales Visit UPC's Sales by Geography


Cumulative Universe Pharmaceuticals Inc's Quick Ratio

UPC's Quick Ratio for the trailling 12 Months

UPC Quick Ratio

(Sep 30 2025)
12 Months
0
12 Months
0
12 Months
0
12 Months
(Sep 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth 290.94 %
Y / Y Cash & cash equivalent TTM Growth 334.49 %
Quick Ratio TTM 2.91
Total Ranking TTM # 3191
Seq. Current Liabilities TTM Growth 3.08 %
Seq. Cash & cash equivalent TTM Growth 2.06 %


On the trailing twelve months basis Due to jump in Current Liabilities in the Q4 2025 to $13,173.93 millions, cumulative Quick Ratio decreased to 2.91 above the UPC average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 414 other companies have achieved higher Quick Ratio than Universe Pharmaceuticals Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from to 3191.

Explain Quick Ratio?
How much Cash & cash equivalents UPC´s has?
What are UPC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 415
Healthcare Sector # 858
Within the Market # 3191


trailing twelve months Quick Ratio Statistics
High Average Low
1.94 1.63 1.35
(Sep 30 2021)   (Sep 30 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2025 MRQ Cash & cash equivalentSep 30 2025 MRQ Current Liabilities
Ataibeckley Inc   6.93 $ 114.606  Millions$ 16.544  Millions
Anaptysbio Inc   6.90 $ 248.956  Millions$ 36.064  Millions
Barinthus Biotherapeutics Plc  6.88 $ 74.272  Millions$ 10.798  Millions
Kalvista Pharmaceuticals Inc   6.86 $ 309.158  Millions$ 45.069  Millions
Revelation Biosciences Inc   6.85 $ 12.708  Millions$ 1.854  Millions
Kezar Life Sciences Inc   6.74 $ 90.216  Millions$ 13.376  Millions
Inmed Pharmaceuticals Inc  6.72 $ 9.443  Millions$ 1.404  Millions
Hepion Pharmaceuticals Inc   6.68 $ 2.321  Millions$ 0.347  Millions
Lexicon Pharmaceuticals Inc   6.66 $ 115.950  Millions$ 17.417  Millions
Talphera Inc   6.63 $ 21.289  Millions$ 3.212  Millions
Crescent Biopharma Inc   6.56 $ 133.265  Millions$ 20.304  Millions
Calcimedica Inc   6.53 $ 14.084  Millions$ 2.158  Millions
Cocrystal Pharma Inc   6.47 $ 7.729  Millions$ 1.194  Millions
Dynavax Technologies Corporation  6.47 $ 647.815  Millions$ 100.142  Millions
Phio Pharmaceuticals Corp  6.43 $ 10.705  Millions$ 1.666  Millions
Korro Bio Inc   6.32 $ 92.479  Millions$ 14.638  Millions
Atossa Therapeutics Inc   6.32 $ 51.955  Millions$ 8.225  Millions
Septerna Inc   6.30 $ 474.346  Millions$ 75.282  Millions
Cogent Biosciences Inc   6.28 $ 390.890  Millions$ 62.246  Millions
Alzamend Neuro Inc   6.20 $ 4.449  Millions$ 0.717  Millions
Apimeds Pharmaceuticals US, Inc.  6.15 $ 6.987  Millions$ 1.135  Millions
Corbus Pharmaceuticals Holdings Inc   6.10 $ 103.982  Millions$ 17.060  Millions
Uniqure N v   5.93 $ 597.056  Millions$ 100.632  Millions
Silence Therapeutics Plc  5.84 $ 102.192  Millions$ 17.512  Millions
Alumis inc   5.77 $ 377.724  Millions$ 65.416  Millions
Arcturus Therapeutics Holdings Inc   5.69 $ 180.360  Millions$ 31.699  Millions
Ars Pharmaceuticals Inc   5.66 $ 288.209  Millions$ 50.877  Millions
Vistagen Therapeutics Inc   5.66 $ 77.175  Millions$ 13.644  Millions
Sensei Biotherapeutics Inc   5.64 $ 25.041  Millions$ 4.436  Millions
Mural Oncology Plc  5.59 $ 58.871  Millions$ 10.530  Millions

Date modified: 2026-10-05T11:03:38+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.